2024-10-19
Recently, Roche (Roche) researchers published in the international top medical journal Nature Medicine entitled: Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial research paper.
The study revealed data from the open-label extension study of Prasinezumab, a monoclonal antibody targeting alpha-synuclein (alpha-SYN) in the PASADENA clinical trial, showing that Prasinezumab has a long-term sustained effect on motor progression in patients with Parkinson's disease.
